Gilteritinib monotherapy as a transplant bridging option for high risk FLT3-mutated AML with t(6;9)(p23;q34.1);DEK-NUP214 in morphological but not cytogenetic or molecular remission following standard induction chemotherapy

We report a case of FLT3-mutated AML with t(6;9) in which induction chemotherapy with DA and midostaurin failed to achieve complete cytogenetic or molecular remission. Due to the COVID-19 pandemic and co-existing cellulitis, monotherapy with the selective FLT3-inhibitor gilteritinib was used as an a...

Descripción completa

Detalles Bibliográficos
Autores principales: Day, James W, Fox, Thomas A, Gupta, Rajeev, Khwaja, Asim, Wilson, Andrew J, Kottaridis, Panagiotis D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844896/
https://www.ncbi.nlm.nih.gov/pubmed/35198371
http://dx.doi.org/10.1016/j.lrr.2022.100291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844896/
https://www.ncbi.nlm.nih.gov/pubmed/35198371
http://dx.doi.org/10.1016/j.lrr.2022.100291

Ejemplares similares